Plan addresses submission decline

Share this article:
FDA says it is banking on its regulatory science initiative to reverse a decline in new drug and biologic submissions and approvals seen over the past few years.
Addressing a Drug Information Association Webinar on regulatory science in January, FDA senior advisor for science, innovation and policy Vicki Seyfert-Margolis said the agency is worried about the downward trend.
New drug and biologic submissions for 2010 sank to the lowest level seen in 15 years—only 26 new drug application and biologic license applications were submitted last year when the average over the past five years has been 32 submissions per year.
Seyfert-Margolis said regulatory science is now being geared to help “de-risk” the drug development process and to identify those key points that are contributing to a decline in the medical product pipeline.
Some examples of projects planned for this include the continuing advancement of genomic-based technologies and high throughput screening tools, both in the area of predictive toxicology and tailored therapies, where genetic or other information helps to select those patients who respond.
Another involves the use of clinical biomarkers which can decrease costs by identifying better responders, reduce trial sample sizes, exclude patients early with the use of toxicity biomarkers, shorten end-point observation times, and allow educated data mining, she said.
Share this article:
You must be a registered member of MMM to post a comment.

Next Article in Features

Email Newsletters


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Read the complete September 2014 Digital Edition

Read the complete September 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.

Medical marketing needs mainstream Mad Men

Medical marketing needs mainstream Mad Men

Agencies must generate emotional resonance with the target audience, not unlike Apple, Pepsi or Nike

Are discounts cutting out co-pays?

GSK's decision to cut Advair's price spurred some PBMs to put it back on formulary. Will drugmaker discounts diminish the need for loyalty programs? How can these programs stay relevant beyond giving co-pay assistance?